Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1960 1
1961 1
1962 2
1964 1
1967 1
1968 1
1992 1
1999 1
2004 2
2005 5
2006 2
2007 4
2008 8
2009 10
2010 4
2011 8
2012 9
2013 3
2014 6
2015 6
2016 16
2017 15
2018 10
2019 11
2020 29
2021 20
2022 20
2023 22

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Ovarian cancer mutational processes drive site-specific immune evasion.
Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP. Vázquez-García I, et al. Among authors: zivanovic o. Nature. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14. Nature. 2022. PMID: 36517593 Free PMC article.
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Zivanovic O, et al. J Clin Oncol. 2021 Aug 10;39(23):2594-2604. doi: 10.1200/JCO.21.00605. Epub 2021 May 21. J Clin Oncol. 2021. PMID: 34019431 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Zamarin D, Burger RA, Sill MW, Powell DJ Jr, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Zamarin D, et al. Among authors: zivanovic o. J Clin Oncol. 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10. J Clin Oncol. 2020. PMID: 32275468 Free PMC article. Clinical Trial.
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Among authors: zivanovic o. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
Why was GOG-0213 a negative trial?
Ehmann S, Zivanovic O, Chi DS. Ehmann S, et al. Among authors: zivanovic o. J Gynecol Oncol. 2021 Jan;32(1):e19. doi: 10.3802/jgo.2021.32.e19. Epub 2020 Dec 2. J Gynecol Oncol. 2021. PMID: 33300314 Free PMC article. No abstract available.
Risk-reducing salpingectomy: Let us be opportunistic.
Long Roche KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O. Long Roche KC, et al. Among authors: zivanovic o. Cancer. 2017 May 15;123(10):1714-1720. doi: 10.1002/cncr.30528. Epub 2017 Mar 23. Cancer. 2017. PMID: 28334425 Free PMC article. Review.
Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes.
Carter J, Abu-Rustum NR, Saban S, Chen LY, Vickers AJ, Tin AL, Billanti G, Connors NA, Broach V, Brown CL, Chi DS, Gardner GJ, Goldfrank DJ, Jewell EL, Leitao MM Jr, Long Roche KC, Mueller JJ, Sonoda Y, Zivanovic O. Carter J, et al. Among authors: zivanovic o. JCO Clin Cancer Inform. 2022 Feb;6:e2100154. doi: 10.1200/CCI.21.00154. JCO Clin Cancer Inform. 2022. PMID: 35239413 Free PMC article. Review.
Ovarian Cancer Treatment - Are We Getting Warmer?
Spriggs DR, Zivanovic O. Spriggs DR, et al. Among authors: zivanovic o. N Engl J Med. 2018 Jan 18;378(3):293-294. doi: 10.1056/NEJMe1714556. N Engl J Med. 2018. PMID: 29342385 No abstract available.
Cytoreductive surgery for advanced ovarian cancer.
Pölcher M, Zivanovic O, Chi DS. Pölcher M, et al. Among authors: zivanovic o. Womens Health (Lond). 2014 Mar;10(2):179-90. doi: 10.2217/whe.14.4. Womens Health (Lond). 2014. PMID: 24601809 Free article. Review.
186 results